In vitro interferon γ improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency

Central European Journal of Immunology

Volumn 40, Issue 1, 2015, Pages 54-60

  Filiz, Serkan ^a   Kocacik Uygun, Dilara F ^b   Köksoy, Sadi ^b   Şahin, Emel ^b   Yeʇin, Olcay ^b  

^a Department of Paediatric Allergy and Immunology Antalya Research and Training Hospital   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Chronic granulomatous disease; Interferon ; Monocytes; Neutrophils

Indexed keywords

DIHYDRORHODAMINE 123; GAMMA INTERFERON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; MULTICENTER STUDY; NEUTROPHIL; PHAGOCYTE; PHAGOCYTOSIS; PROTEIN EXPRESSION; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2 DEFICIENCY; RESPIRATORY BURST;

EID: 84928476500     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2015.50833     Document Type: Article

References (22)

1. Rosenzweig SD, Holland SM (2004): Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 113: 620-626.
2. Holland SM (2010): Chronic granulomatous disease. Clinic Rev Allerg Immunol 38: 3-10.
3. de Oliveira-Junior EB, Bustamante J, Newburger PE, et al. (2011): The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol 73: 420-427.
4. Song E, Jaishankar GB, Saleh H, et al. (2011): Chronic granulomatous diseases: a review of the infectious and inflammatory complications. Clin Mol Allergy 9: 1-14.
5. Kang EM, Marciano BE, De Ravin S (2011): Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 127: 1319-1326.
6. Saha B, Prasanna SJ, Chandrasekar B, Nandi D (2010): Gene modulation and immunoregulatory roles of interferon-γ. Cytokine 50: 1-14.
7. Ezekowitz RA, Orkin SH, Newburger PE (1987): Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 80: 1009-1016.
8. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group (1991): N Engl J Med 324: 509-516.
9. Woodman RC, Erickson RW, Rae J, et al. (1992): Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 79: 1558-1562.
10. Weening RS, Leitz GJ, Seger RA (1995): Recombinant human interferon-gamma in patients with chronic granulomatous disease-European follow-up. Eur J Pediatr 154: 295-298.
11. Jackson SH, Miller GF, Segal BH, et al. (2001): IFN-γ is effective in reducing infections in the mouse model of chronic granulomatous disease. J Interferon Cytokine Res 21: 567-573.
12. Marciano BE, Wesley R, De Carlo ES, et al. (2004): Longterm interfeon-γ therapy for patients with chronic granulomatous disease. Clin Infect Dis 39: 692-699.
13. Hawley TS, Hawley RG (eds.) (2004): Methods in Molecular Biology: Flow Cytometry Protocols. 3rd ed. Humana Press Inc. Totowa, NJ.
14. Epling CL, Stites DP, McHugh TM, et al. (1992): Neutrophil function screening in patients with chronic granulomatous disease by a flow cytometric method. Cytometry 13: 615-20.
15. Ishibashi F, Mizukami T, Kanegasaki S, et al. (2001): Improved superoxide-generating ability by interferon-γ due to splicing pattern change of transcripts in neutrophils from patients with splice site mutation in CYBB. Blood 98: 436-441.
16. Newburger PE, Ezekowitz RAB, Whitney C, et al. (1988): Introduction of phagocyte cytochrome b heavy chain gene expression by interferon-γ. Proc Natl Acad Sci U S A 85: 5215-5219.
17. Cassatella MA, Bazzoni F, Flynn RM, et al. (1990): Molecular basis of interferon-γ and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components. J Biol Chem 265: 20241-20246.
18. Ahlin A, Elinder G, Palmblad J (1997): Dose-dependent enhancements by interferon-γ on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89: 3396-3401.
19. Condino-Neto A, Newburger PE (2000): Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splicing site consensus region mutation. Blood 95: 3548-3554.
20. Filiz S, Kocacl k Uygun DF, Sanal O, et al. (2013): The demographic datas of chronic granulomatous disease patients and the comparation of the clinical datas before and after interferon-gamma treatment in our country. Asthma Allergy Immunology 11: 152-161.
21. Miller CH, Maher SG, Young HA (2009). Clinical use of interferon-γ. Ann N Y Acad Sci 1182: 69-79.
22. Errante PR, Frazao JB, Condino-Neto A (2008): The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 3: 225-230.